SCHEMBL15988707

SCHEMBL15988707

Cc1ccc(C(=O)CCC(=O)c2cccc(C(F)(F)F)c2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTNNB1 P35222 1/20 0.52
▸ WNT3A P56704 1/20 0.52
▸ CES2 O00748 1/20 0.49
▸ KMT2A Q03164 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ POLB P06746 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.44
▸ ACHE P22303 1/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SRD5A2 P31213 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.42
▸ TAS1R1 Q7RTX1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15988706 0.83 MMP1 (0.54) CES2KMT2AALDH1A1MAPTHDAC1
SCHEMBL15979688 0.82 CTNNB1 (0.54) CTNNB1WNT3AKMT2AMEN1ALDH1A1
SCHEMBL3032732 0.79 CTNNB1 (0.60) CTNNB1WNT3ACES2KMT2AMEN1
SCHEMBL15988679 0.78 ALDH1A1 (0.58) CTNNB1WNT3ACES2KMT2AMEN1
SCHEMBL10471221 0.78 DAO (0.53) CTNNB1WNT3AKMT2AMEN1ALDH1A1
SCHEMBL15980075 0.78 CTNNB1 (0.60) CTNNB1WNT3ACES2KMT2AMEN1
SCHEMBL744906 0.77 CTNNB1 (0.62) CTNNB1WNT3ACES2KMT2AMEN1
SCHEMBL9468405 0.77 ALDH1A1 (0.61) CTNNB1WNT3ACES2KMT2AMEN1
SCHEMBL15979700 0.76 DAO (0.61) KMT2AMEN1ALDH1A1POLBRAB9A
SCHEMBL8384433 0.76 CTNNB1 (0.60) CTNNB1WNT3ACES2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 — — US disclosed
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 — — US disclosed
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 — — US disclosed
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-02-23 — — US disclosed
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2022-03-24 — — US disclosed
US-11077046-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-11034682-B2 Gamma-diketones as wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2021-06-15 — — US disclosed
US-20200222295-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES MED-PATHWAYS II LIMITED (VG) 2020-07-16 — — US disclosed
US-20200223834-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2020-07-16 — — US disclosed
US-10457672-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2019-10-29 — — US disclosed
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-07-12 — — US disclosed
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-07-12 — — US disclosed
US-9951053-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2018-04-24 — — US disclosed
US-9795550-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles SAMUMED, LLC (US) 2017-10-24 — — US disclosed
US-9795550-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles SAMUMED, LLC (US) 2017-10-24 — — US disclosed
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2017-09-14 — — US disclosed
US-20160206540-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2016-07-21 — — US disclosed
US-20160206540-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2016-07-21 — — US disclosed
WO-2016029021-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES SAMUMED, LLC (US) 2016-02-25 — — WO disclosed
WO-2014130869-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS SAMUMED, LLC (US) 2014-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077046-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885CES2 4435/4885
US-20200223834-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885CES2 4753/4885
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885CES2 4435/4885
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885CES2 4435/4885
US-20200222295-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885CES2 4435/4885
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885CES2 4753/4885
US-20160206540-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CTNNB1 1789/4885WNT3A 1618/4885CES2 4435/4885
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles DGKG, DGKA, DNER CTNNB1 1475/4885WNT3A 1983/4885CES2 3982/4885
US-10457672-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CTNNB1 5/4885WNT3A 4/4885CES2 4749/4885
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885CES2 4753/4885
US-11034682-B2 Gamma-diketones as wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885CES2 4768/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CTNNB1 5/4885WNT3A 4/4885CES2 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback